Literature DB >> 8504055

Successful treatment of Sweet's syndrome with doxycycline.

R K Joshi1, D N Atukorala, A Abanmi, O al Khamis, A Haleem.   

Abstract

Two patients with Sweet's syndrome are described, both of whom were treated with doxycycline 200 mg daily, and responded well to therapy. Doxycycline appears to be an effective alternative to corticosteroids for the treatment of Sweet's syndrome.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8504055     DOI: 10.1111/j.1365-2133.1993.tb00242.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  6 in total

1.  Sweet syndrome secondary to inflammatory bowel disease.

Authors:  Malcolm M Wells; William Stecho; Bret Wehrli; Nitin Khanna
Journal:  Can J Gastroenterol       Date:  2013-03       Impact factor: 3.522

Review 2.  Tetracyclines-An Important Therapeutic Tool for Dermatologists.

Authors:  Malgorzata Orylska-Ratynska; Waldemar Placek; Agnieszka Owczarczyk-Saczonek
Journal:  Int J Environ Res Public Health       Date:  2022-06-13       Impact factor: 4.614

Review 3.  Management of cutaneous disorders related to inflammatory bowel disease.

Authors:  Zaira Pellicer; Jesus Manuel Santiago; Alejandro Rodriguez; Vicent Alonso; Rosario Antón; Marta Maia Bosca
Journal:  Ann Gastroenterol       Date:  2012

Review 4.  Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.

Authors:  Philip R Cohen
Journal:  Orphanet J Rare Dis       Date:  2007-07-26       Impact factor: 4.123

Review 5.  Anti-inflammatory and Immunomodulatory Effects of Antibiotics and Their Use in Dermatology.

Authors:  Swetalina Pradhan; Bhushan Madke; Poonam Kabra; Adarsh Lata Singh
Journal:  Indian J Dermatol       Date:  2016 Sep-Oct       Impact factor: 1.494

Review 6.  The Development of Third-Generation Tetracycline Antibiotics and New Perspectives.

Authors:  Aura Rusu; Emanuela Lorena Buta
Journal:  Pharmaceutics       Date:  2021-12-05       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.